KLRK1 and myeloid sarcoma: In autoimmune diseases such as MS, T1DM, and CeD, NKG2D can be induced to be expressed in the corresponding lymphocytes, so as to respond to the overexpression of NKG2D-L self-cells to produce a killing effect (as shown in Table 2).